Close Menu
Home › Columbia U Team to Study Biocept Liquid Biopsy Platform in Breast Cancer

Columbia U Team to Study Biocept Liquid Biopsy Platform in Breast Cancer

Dec 27, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Biocept said today that Columbia University Medical Center is planning a study that will evaluate its Target Selector liquid biopsy platform for detecting leptomeningeal metastases in patients with breast cancer.

LM is a condition in which cancer cells gain access to the cerebral spinal fluid, allowing them to seed metastases in the nerve tissue of the spine and brain.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov
14
Featured Webinar

High-Performance Variant Detection in Somatic Cancer Testing with an Integrated NGS Solution

Sponsored by
Qiagen

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

Dec
02
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.   

What's Popular?

In Molecular Diagnostics

  1. Ancestry Begins Genetic Testing Services for Health

    Premium

  2. Natera Plans Stock Offering Worth up to $201.3M; Expects Q3 Revenue Gain Above Consensus Estimate

  3. Abbott Q3 Diagnostics Revenues Rise 5 Percent, MDx Revenues Decline

  4. Inivata Collecting Evidence for Liquid Biopsy in Immunotherapy Prediction, Response Monitoring

    Premium

  5. Exact Sciences, Mayo Clinic Launch Real-World Impact Study for Cologuard

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.